Back to Search
Start Over
Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment
- Source :
- Current Medical Research and Opinion. 34:995-1003
- Publication Year :
- 2018
- Publisher :
- Informa UK Limited, 2018.
-
Abstract
- To assess glycemic effectiveness, adherence and persistence within 6 months of treatment initiation with dulaglutide, a once weekly GLP-1 receptor agonist, in a US real-world setting.This retrospective claims analysis included adults (≥18 years) with T2DM from the HealthCore Integrated Research Database, who had HbA1c laboratory results around initiation and within 6 months after initiation. Glycemic control was assessed by change in HbA1c from pre-initiation to post-initiation. Patients were considered adherent if their proportion of days covered (PDC) was ≥0.80; persistence was measured as days of continuous therapy from initiation to 6 months after initiation with no gaps45 days between fills.Of the 308 analyzed patients, the majority (n = 188; 61%) were adherent to dulaglutide (mean PDC 0.76; SD 0.26), with 115 patients (37%) discontinuing treatment. Mean persistence was 152 days/5 months. Mean HbA1c decreased from 8.49% (SD 1.70, median 8.20%) at baseline to 7.59% (SD 1.51, median 7.30%) at follow-up, corresponding to a mean HbA1c change of -0.90% (95% confidence interval [CI] -1.08 to -0.73; p .01; median -0.70%). Patients who were adherent to or persistent with dulaglutide experienced larger reductions (-1.14% and -1.12% respectively), as did those without prior GLP-1 RA use (-1.03%). The proportion of patients with HbA1c7% increased from 18% to 40%.Dulaglutide was associated with a significant decrease in HbA1c levels 6 months after treatment initiation. Patients who adhered to or persisted with dulaglutide therapy, or were naïve to GLP-1 RA use, experienced greater decreases in HbA1c levels.
- Subjects :
- Adult
Blood Glucose
Male
Agonist
medicine.medical_specialty
medicine.drug_class
Recombinant Fusion Proteins
Glucagon-Like Peptides
Once weekly
030209 endocrinology & metabolism
Drug Administration Schedule
Persistence (computer science)
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Hypoglycemic Agents
030212 general & internal medicine
Retrospective Studies
Glycemic
business.industry
Type 2 Diabetes Mellitus
General Medicine
Middle Aged
Immunoglobulin Fc Fragments
Diabetes Mellitus, Type 2
Female
Dulaglutide
business
medicine.drug
Subjects
Details
- ISSN :
- 14734877 and 03007995
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Current Medical Research and Opinion
- Accession number :
- edsair.doi.dedup.....f610cd765b88cf5525ad926883f6786b